Showing 3,261 - 3,280 results of 18,449 for search 'significant ((((teer decrease) OR (((a decrease) OR (greater decrease))))) OR (mean decrease))', query time: 0.69s Refine Results
  1. 3261

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  2. 3262

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  3. 3263

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  4. 3264

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  5. 3265

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  6. 3266

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  7. 3267
  8. 3268

    A Novel Type of PSMA-Targeting Ligands via β‑Branched Aromatic α‑Amino Acid Modification, Bearing Enhanced Tumor Targeting and Reduced Renal Toxicity by Zong-Xiao Liu (22177765)

    Published 2025
    “…With average renal uptake of less than 10%ID/g, as opposed to 25%ID/g for [<sup>68</sup>Ga]Ga-<b>PSMA-617</b>, this substantial decrease in renal accumulation translates to a significantly improved safety profile by minimizing nephrotoxic risks. …”
  9. 3269

    A Novel Type of PSMA-Targeting Ligands via β‑Branched Aromatic α‑Amino Acid Modification, Bearing Enhanced Tumor Targeting and Reduced Renal Toxicity by Zong-Xiao Liu (22177765)

    Published 2025
    “…With average renal uptake of less than 10%ID/g, as opposed to 25%ID/g for [<sup>68</sup>Ga]Ga-<b>PSMA-617</b>, this substantial decrease in renal accumulation translates to a significantly improved safety profile by minimizing nephrotoxic risks. …”
  10. 3270
  11. 3271
  12. 3272
  13. 3273
  14. 3274
  15. 3275
  16. 3276
  17. 3277
  18. 3278

    Particle size distribution of GO-GA NPs. by Huda H. Elbehery (22492996)

    Published 2025
    “…The inclusion of GO-GA NPs at LC<sub>40</sub> had a significant post-effect on progeny production of <i><i>C. maculatus</i></i>, resulting in a significant reduction in the number of deposited eggs and adult emergence, which led to a significant decrease in the percentage of adult emergence to 15.23 ± 5.46 compared to 61.33 ± 2.94, as observed in the GO treatment. …”
  19. 3279

    GC-MS chromatogram of garlic essential oil. by Huda H. Elbehery (22492996)

    Published 2025
    “…The inclusion of GO-GA NPs at LC<sub>40</sub> had a significant post-effect on progeny production of <i><i>C. maculatus</i></i>, resulting in a significant reduction in the number of deposited eggs and adult emergence, which led to a significant decrease in the percentage of adult emergence to 15.23 ± 5.46 compared to 61.33 ± 2.94, as observed in the GO treatment. …”
  20. 3280